Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth

Yujun Dong, Jiahua Qian, Ramy Ibrahim, Jay A. Berzofsky, Samir N. Khleif

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalJournal of Immunotherapy
Issue number1
StatePublished - Jan 2006


  • Angiogenesis
  • Cancer vaccine
  • Cytotoxic T lymphocytes
  • Immunotherapy
  • MHC Class 1 epitopes
  • VEGFR2 (FLK-1, KDR)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Identification of H-2D<sup>b</sup>-specific CD8<sup>+</sup> T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth'. Together they form a unique fingerprint.

Cite this